β-Hydroxy-β-methylbutyrate (HMB) prevents sepsis-induced diaphragm dysfunction in mice

Respiratory Physiology and Neurobiology

Volumn 196, Issue 1, 2014, Pages 63-68

  Supinski, Gerald S ^a   Callahan, Leigh A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Hydroxy methylbutyrate (HMB); Caspase 3; Diaphragm; PKR; Proteolysis; Sepsis

Indexed keywords

BETA HYDROXY BETA METHYLBUTYRATE; BUTYRIC ACID DERIVATIVE; CALPAIN; CASPASE 3; DOUBLE STRANDED RNA; ENDOTOXIN; LIPOPOLYSACCHARIDE; PROTEIN KINASE; UNCLASSIFIED DRUG; BETA-HYDROXYISOVALERIC ACID; CASP3 PROTEIN, MOUSE; MUSCLE RELAXANT AGENT; PROTEASOME; PROTEIN KINASE R; VALERIC ACID DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DIAPHRAGM; DIAPHRAGM DISEASE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; MALE; MOUSE; MUSCLE EXCITATION; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; SEPSIS; STIMULATION; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MUSCLE WEAKNESS; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION;

ANIMALS; CALPAIN; CASPASE 3; DIAPHRAGM; DISEASE MODELS, ANIMAL; EIF-2 KINASE; LIPOPOLYSACCHARIDES; MALE; MICE; MUSCLE STRENGTH; MUSCLE WEAKNESS; NEUROMUSCULAR AGENTS; ORGAN SIZE; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; SEPSIS; VALERATES;

EID: 84897842977     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2014.02.015     Document Type: Article

References (29)

1. Baxter J.H., Carlos J.L., Thurmond J., Rehani R.N., Bultman J., Frost D. Dietary toxicity of calcium β-hydroxy-beta-methyl butyrate (CaHMB). Food Chem. Toxicol. 2005, 43:1731-1741.
2. Close R.I. Dynamic properties of mammalian skeletal muscles. Physiol. Rev. 1972, 52:129-197.
3. Demoule A., Jung B., Prodanovic H., Molinari N., Chanques G., Coirault C., Matecki S., Duguet A., Similowski T., Jaber S. Diaphragm dysfunction on admission to ICU: prevalence, risk factors and prognostic impact - a prospective study. Am. J. Respir. Crit. Care Med. 2013, 188:213-219.
4. Eley H.L., Russell S.T., Tisdale M.J. Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1417-E1426.
5. Flakoll P., Sharp R., Baier S., Levenhagen D., Carr C., Nissen S. Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women. Nutrition 2004, 20:445-451.
6. Gallagher P.M., Carrithers J.A., Godard M.P., Schulze K.E., Trappe S.W. Beta-hydroxy-beta-methylbutyrate ingestion, part II: effects on hematology, hepatic and renal function. Med. Sci. Sports Exerc. 2000, 32:2116-2119.
7. Hao Y., Jackson J.R., Wang Y., Edens N., Pereira S.L., Alway S.E. Beta-hydroxy-beta-methylbutyrate reduces myonuclear apoptosis during recovery from hind limb suspension-induced muscle fiber atrophy in aged rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301:R701-R715.
8. Hermans G., Agten A., Testelmans D., Decramer M., Gayan-Ramirez G. Increased duration of mechanical ventilation is associated with decreased diaphragmatic force: a prospective observational study. Crit. Care 2010, 14:R127.
9. Higuchi M., Tomioka M., Takano J., Shirotani K., Iwata N., Masumoto H., Maki M., Itohara S., Saido T.C. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J. Biol. Chem. 2005, 280:15229-15237.
10. Katta A., Kakarla S.K., Manne N.D., Wu M., Kundla S., Kolli M.B., Nalabotu S.K., Blough E.R. Diminished muscle growth in the obese Zucker rat following overload is associated with hyperphosphorylation of AMPK and dsRNA-dependent protein kinase. J. Appl. Physiol. (1985) 2012, 113:377-384.
11. Klaude M., Mori M., Tjader I., Gustafsson T., Wernerman J., Rooyackers O. Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis. Clin. Sci. (Lond.) 2012, 122:133-142.
12. Kornasio R., Riederer I., Butler-Browne G., Mouly V., Uni Z., Halevy O. Beta-hydroxy-beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways. Biochim. Biophys. Acta 2009, 1793:755-763.
13. Laghi F., Cattapan S.E., Jubran A., Parthasarathy S., Warshawsky P., Choi Y.S., Tobin M.J. Is weaning failure caused by low-frequency fatigue of the diaphragm?. Am. J. Respir. Crit. Care Med. 2003, 167:120-127.
14. May P.E., Barber A., D'Olimpio J.T., Hourihane A., Abumrad N.N. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine. Am. J. Surg. 2002, 183:471-479.
15. Morel M., Couturier J., Pontcharraud R., Gil R., Fauconneau B., Paccalin M., Page G. Evidence of molecular links between PKR and mTOR signalling pathways in Abeta neurotoxicity: role of p53, Redd1 and TSC2. Neurobiol. Dis. 2009, 36:151-161.
16. Nissen S., Sharp R.L., Panton L., Vukovich M., Trappe S., Fuller J.C. Beta-hydroxy-beta-methylbutyrate (HMB) supplementation in humans is safe and may decrease cardiovascular risk factors. J. Nutr. 2000, 130:1937-1945.
17. Rathmacher J.A., Nissen S., Panton L., Clark R.H., Eubanks May P., Barber A.E., D'Olimpio J., Abumrad N.N. Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters. JPEN J. Parenter. Enteral. Nutr. 2004, 28:65-75.
18. Russell S.T., Siren P.M., Siren M.J., Tisdale M.J. Mechanism of attenuation of protein loss in murine C2C12 myotubes by d-myo-inositol 1,2,6-triphosphate. Exp. Cell Res. 2010, 316:286-295.
19. Russell S.T., Tisdale M.J. Mechanism of attenuation by beta-hydroxy-beta-methylbutyrate of muscle protein degradation induced by lipopolysaccharide. Mol. Cell Biochem. 2009, 330:171-179.
20. Smith H.J., Mukerji P., Tisdale M.J. Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss. Cancer Res. 2005, 65:277-283.
21. Supinski G.S., Callahan L.A. Caspase activation contributes to endotoxin-induced diaphragm weakness. J. Appl. Physiol. 2006, 100:1770-1777.
22. Supinski G.S., Callahan L.A. Calpain activation contributes to endotoxin-induced diaphragmatic dysfunction. Am. J. Respir. Cell Mol. Biol. 2010, 42:80-87.
23. Supinski G.S., Callahan L.A. Double-stranded RNA-dependent protein kinase activation modulates endotoxin-induced diaphragm weakness. J. Appl. Physiol. 2011, 110:199-205.
24. Supinski G.S., Callahan L.A. Diaphragm weakness in mechanically ventilated critically ill patients. Crit. Care 2013, 17:R120.
25. Supinski G.S., Ji X., Callahan L.A. The JNK MAP kinase pathway contributes to the development of endotoxin-induced diaphragm caspase activation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 297:R825-R834.
26. Supinski G.S., Ji X.Y., Callahan L.A. p38 mitogen-activated protein kinase modulates endotoxin-induced diaphragm caspase activation. Am. J. Respir. Cell Mol. Biol. 2010, 43:121-127.
27. Takano J., Tomioka M., Tsubuki S., Higuchi M., Iwata N., Itohara S., Maki M., Saido T.C. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J. Biol. Chem. 2005, 280:16175-16184.
28. Watson A.C., Hughes P.D., Louise Harris M., Hart N., Ware R.J., Wendon J., Green M., Moxham J. Measurement of twitch transdiaphragmatic, esophageal, and endotracheal tube pressure with bilateral anterolateral magnetic phrenic nerve stimulation in patients in the intensive care unit. Crit. Care Med. 2001, 29:1325-1331.
29. Wilson J.M., Fitschen P.J., Campbell B., Wilson G.J., Zanchi N., Taylor L., Wilborn C., Kalman D.S., Stout J.R., Hoffman J.R., Ziegenfuss T.N., Lopez H.L., Kreider R.B., Smith-Ryan A.E., Antonio J. International Society of Sports Nutrition Position Stand: beta-hydroxy-beta-methylbutyrate (HMB). J. Int. Soc. Sports Nutr. 2013, 10:6.